SA517381981B1 - أجسام مضادة لترانس ثيرتين - Google Patents
أجسام مضادة لترانس ثيرتينInfo
- Publication number
- SA517381981B1 SA517381981B1 SA517381981A SA517381981A SA517381981B1 SA 517381981 B1 SA517381981 B1 SA 517381981B1 SA 517381981 A SA517381981 A SA 517381981A SA 517381981 A SA517381981 A SA 517381981A SA 517381981 B1 SA517381981 B1 SA 517381981B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- ttr
- antibodies
- transthyretin
- accumulation
- amyloidosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
أجسام مضادة لترانس ثيرتين ANTI-TRANSTHYRETIN ANTIBODIES الملخـــص يتعلق الاختراع الحالي بتوفير أجسام مضادة antibodies ترتبط بشكل خاص بترانس ثيرتين transthyretin (TTR). يمكن استخدام الأجسام المضادة antibodies لعلاج أو تفعيل الوقاية effecting prophylaxis من الأمراض diseases أو الاضطرابات disorders المصحوبة بتراكم TTR TTR accumulation أو تراكم رواسب TTR accumulation of TTR deposits (على سبيل المثال، الداء النشواني amyloidosis الناتج عن TTR). يمكن أيضًا استخدام الأجسام المضادة antibodies لتشخيص الداء النشواني amyloidosis الناتج عن TTR وتثبيط أو خفض تَكَدُّس TTR reducing aggregation of TTR، من بين تطبيقات أخرى. الشكل 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109004P | 2015-01-28 | 2015-01-28 | |
| US201562266555P | 2015-12-11 | 2015-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA517381981B1 true SA517381981B1 (ar) | 2022-05-17 |
Family
ID=55300737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA517381981A SA517381981B1 (ar) | 2015-01-28 | 2017-07-25 | أجسام مضادة لترانس ثيرتين |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20160257737A1 (ar) |
| EP (1) | EP3250593B1 (ar) |
| JP (1) | JP7101927B2 (ar) |
| KR (1) | KR102649788B1 (ar) |
| CN (1) | CN107406500B (ar) |
| AU (1) | AU2016210889C1 (ar) |
| BR (1) | BR112017016345A2 (ar) |
| CA (1) | CA2974993A1 (ar) |
| CO (1) | CO2017008482A2 (ar) |
| CU (1) | CU20170098A7 (ar) |
| DK (1) | DK3250593T3 (ar) |
| EA (1) | EA036014B1 (ar) |
| ES (1) | ES2925716T3 (ar) |
| HR (1) | HRP20220918T1 (ar) |
| HU (1) | HUE059592T2 (ar) |
| MX (1) | MX2017009803A (ar) |
| MY (1) | MY193701A (ar) |
| PE (1) | PE20180218A1 (ar) |
| PL (1) | PL3250593T3 (ar) |
| PT (1) | PT3250593T (ar) |
| RS (1) | RS63513B1 (ar) |
| SA (1) | SA517381981B1 (ar) |
| SG (2) | SG11201706126WA (ar) |
| SI (1) | SI3250593T1 (ar) |
| TW (2) | TWI711631B (ar) |
| WO (1) | WO2016120811A1 (ar) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3478716A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| KR20200074956A (ko) | 2017-10-06 | 2020-06-25 | 프로테나 바이오사이언시즈 리미티드 | 항-트랜스타이레틴 항체 |
| BR112020010483A2 (pt) | 2017-11-29 | 2020-10-20 | Prothena Biosciences Limited | formulação liofilizada de um anticorpo monoclonal contra transtirretina |
| WO2020003172A1 (en) | 2018-06-26 | 2020-01-02 | Mor Research Applications | Transthyretin antibodies and uses thereof |
| CN111018976B (zh) * | 2018-10-10 | 2022-04-01 | 东莞市朋志生物科技有限公司 | 一种抗人心肌肌钙蛋白i的重组抗体 |
| EP3876713A1 (en) * | 2018-11-09 | 2021-09-15 | Neurimmune AG | Patient-derived amyloid xenograft non-human animal model |
| SG11202112762TA (en) * | 2019-07-08 | 2021-12-30 | Amgen Inc | Multispecific transthyretin immunoglobulin fusions |
| CN116804186B (zh) * | 2023-07-05 | 2023-12-22 | 中国兽医药品监察所 | 一种抗鸡传染性贫血病毒单克隆抗体杂交瘤细胞株、单克隆抗体、试剂或试剂盒及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| DE60045319D1 (de) | 1999-02-05 | 2011-01-13 | Samsung Electronics Co Ltd | Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| CA2471849A1 (en) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| CA2507664C (en) | 2002-11-29 | 2010-09-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| PL1820022T3 (pl) | 2004-11-10 | 2009-11-30 | Boehringer Ingelheim Pharma | Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika |
| EP2808020A1 (en) | 2006-04-21 | 2014-12-03 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Beta-Amyloid Pet Imaging Agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| DK2126093T3 (da) | 2007-03-02 | 2013-01-07 | Boehringer Ingelheim Pharma | Forbedring af proteinfremstilling |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| JP2010195710A (ja) * | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| UA118441C2 (uk) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| WO2014124334A2 (en) | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| WO2015010118A2 (en) * | 2013-07-19 | 2015-01-22 | The University Of Texas | Transthyretin amyloid-selective and polyreactive catabodies |
-
2016
- 2016-01-27 TW TW105102532A patent/TWI711631B/zh active
- 2016-01-27 TW TW109138086A patent/TWI769570B/zh active
- 2016-01-28 MX MX2017009803A patent/MX2017009803A/es unknown
- 2016-01-28 US US15/009,667 patent/US20160257737A1/en not_active Abandoned
- 2016-01-28 MY MYPI2017702752A patent/MY193701A/en unknown
- 2016-01-28 SG SG11201706126WA patent/SG11201706126WA/en unknown
- 2016-01-28 JP JP2017540250A patent/JP7101927B2/ja active Active
- 2016-01-28 CA CA2974993A patent/CA2974993A1/en active Pending
- 2016-01-28 PT PT167029909T patent/PT3250593T/pt unknown
- 2016-01-28 EA EA201791710A patent/EA036014B1/ru unknown
- 2016-01-28 PE PE2017001289A patent/PE20180218A1/es unknown
- 2016-01-28 HR HRP20220918TT patent/HRP20220918T1/hr unknown
- 2016-01-28 SG SG10201906696RA patent/SG10201906696RA/en unknown
- 2016-01-28 ES ES16702990T patent/ES2925716T3/es active Active
- 2016-01-28 CU CUP2017000098A patent/CU20170098A7/es unknown
- 2016-01-28 WO PCT/IB2016/050416 patent/WO2016120811A1/en active Application Filing
- 2016-01-28 KR KR1020177023750A patent/KR102649788B1/ko active IP Right Grant
- 2016-01-28 RS RS20220788A patent/RS63513B1/sr unknown
- 2016-01-28 PL PL16702990.9T patent/PL3250593T3/pl unknown
- 2016-01-28 DK DK16702990.9T patent/DK3250593T3/da active
- 2016-01-28 EP EP16702990.9A patent/EP3250593B1/en active Active
- 2016-01-28 SI SI201631572T patent/SI3250593T1/sl unknown
- 2016-01-28 AU AU2016210889A patent/AU2016210889C1/en active Active
- 2016-01-28 BR BR112017016345A patent/BR112017016345A2/pt active Search and Examination
- 2016-01-28 CN CN201680015343.2A patent/CN107406500B/zh active Active
- 2016-01-28 HU HUE16702990A patent/HUE059592T2/hu unknown
-
2017
- 2017-07-25 SA SA517381981A patent/SA517381981B1/ar unknown
- 2017-08-22 CO CONC2017/0008482A patent/CO2017008482A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501318B1 (en) | Anti-transthyretin antibodies | |
| SA517381991B1 (ar) | أجسام مضادة لترانس ثيرتين | |
| SA517381981B1 (ar) | أجسام مضادة لترانس ثيرتين | |
| WO2018007924A3 (en) | Anti-transthyretin antibodies | |
| MX2020003041A (es) | Anticuerpos anti-transtiretina. | |
| WO2018007923A3 (en) | Anti-transthyretin antibodies | |
| WO2018007922A3 (en) | Anti-transthyretin antibodies | |
| MX2020002694A (es) | Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas. | |
| MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| MX2018006385A (es) | Moleculas de anticuerpo contra april y usos de las mismas. | |
| PH12020550141A1 (en) | Antibody molecules to cd138 and uses thereof | |
| MX2021016098A (es) | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. | |
| CL2020002468A1 (es) | Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018) | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
| MY193688A (en) | Anti-transthyretin antibodies | |
| EA202090891A1 (ru) | Молекулы антител против cd138 и их применение | |
| EA202090898A1 (ru) | Антитранстиретиновые антитела | |
| PH12020552202A1 (en) | Antibody molecules to complement component 5 and uses thereof | |
| NZ730759A (en) | 1,2-benzothiazole compounds for the treatment of kidney disorders |